Anthropic CEO Dario Amodei has predicted that artificial intelligence could help cure or prevent most human diseases within five to 10 years, placing advances in biology and medicine among the potential long-term applications of increasingly capable AI systems.
Amodei recently reiterated the forecast while discussing how the AI industry could build greater public trust through measurable scientific outcomes. He argued that breakthroughs against diseases such as cancer would demonstrate the technology's value more effectively than efforts focused primarily on improving public perceptions of AI.
The prediction builds on Amodei's 2024 essay, "Machines of Loving Grace," in which he outlined what he calls the "compressed 21st century." His central argument is that powerful AI could enable researchers to achieve 50 to 100 years of progress in biology and medicine within five to 10 years.
Amodei's projections include the prevention and treatment of nearly all natural infectious diseases, elimination of most cancers, more effective prevention and treatment of genetic diseases, and advances against Alzheimer's. He has also suggested that AI-assisted biological research could contribute to improved treatments for conditions including diabetes, obesity, heart disease and autoimmune disorders.
Former OpenAI executive and ChronicleBio co-founder Fidji Simo has also expressed optimism about AI's potential in medicine, while highlighting a key limitation. Simo has argued that more capable AI models alone will not be enough and that progress will also depend on access to high-quality, disease-specific biological data.
Cancer may be comparatively well positioned for AI-assisted research because decades of investment have generated substantial biological and clinical datasets. Complex chronic diseases could present a different challenge where the necessary research infrastructure and datasets are less developed.
AI is already being applied to parts of drug discovery, including identifying potential drug targets, analysing molecular interactions and supporting research workflows. However, these applications do not remove established requirements for laboratory studies, clinical trials, regulatory review and evidence of safety and effectiveness before new treatments reach patients.
Amodei has himself acknowledged physical-world constraints on the pace of progress, including data availability, biological complexity and the time required for experiments and clinical trials. His five-to-10-year timeline therefore remains a prediction rather than an established medical or scientific forecast.
The discussion comes as AI companies increasingly position scientific research and healthcare as potential areas for advanced models. For the sector, the focus is gradually extending from what AI systems can generate digitally to whether they can contribute to verifiable advances in research, drug development and patient outcomes.
Disclaimer: This article may include information derived from interviews, press releases, public statements, research, company communications and other publicly available or third-party sources. Such material may be summarised, paraphrased or contextualised for journalistic and editorial purposes. All rights in third-party content remain with their respective owners.